Close Menu
Alnylam Pharmaceuticals last week gave a quick glimpse into one of its early-stage drug-development programs, showing preclinical data that suggest siRNAs targeting PCSK9 could cut cholesterol levels in mice by as much as 30 percent.
 
However, Alnylam researcher Akin Akinc, who presented the data at the second annual meeting of the Oligonucleotide Therapeutics Society held at Rockefeller University in New York, stressed that the results were preliminary and came from early-stage screening experiments.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.